Biophan to Present at Licensing Executives Society Conference; Presentation to Highlight Business Model to Commercialize Extensive Biomedical Technology Portfolio
Biophan executives will highlight the Company's strategy for revenue growth through commercialization of its extensive intellectual property portfolio. Biophan is a development leader with a portfolio of 156 U.S. patents, applications and licenses, as well as additional international patents and applications.
“We're a prolific innovator. We have vigorously protected our technological developments by establishing a strong U.S. and international patent portfolio”
The conference is expected to draw some of the most influential executives and decision-makers in the licensing world. Biophan is committed to introducing a wide range of products to market through strategic joint ventures and licensing agreements with major manufacturing companies.
"Biophan's research and development programs have yielded a broad array of patented biomedical solutions, related to magnetic resonance imaging (MRI) visualization of restenosis in stents, MR image compatible vena cava filters, enhanced MRI contrast agents, active and controllable drug delivery, long-lasting power systems using bio-thermal energy and others," said Michael Weiner, Biophan CEO. "We recently licensed a number of our technologies to Boston Scientific in a $5 million dollar-plus licensing and equity agreement that we believe is only the first such agreement of many for Biophan in the months and years ahead."
Many large corporations, professional firms, and universities comprise the Licensing Executives Society's membership. We believe that their conference provides an important forum for Biophan to continue ongoing efforts to increase visibility about its technology leadership in the biomedical industry.
"We're a prolific innovator. We have vigorously protected our technological developments by establishing a strong U.S. and international patent portfolio," said Mr. Weiner. "We believe that this business strategy will lead to significant revenue growth for Biophan, as we partner with companies to take these technologies to market."
Kicking off the 2005 LES Annual Meeting will be Senior IP executives from Philips, Merck, IBM, Genentech Procter & Gamble, Sanofi-Aventias and other major corporations, according to event organizers. The executives are scheduled to discuss the ways in which their licensing programs became successful, the challenges they face and thoughts about the future of licensing and new business models.
About Licensing Executives Society
Established in 1965, the Licensing Executives Society (U.S.A. and Canada), Inc. (LES) is a professional society comprised of over 6,000 members engaged in the transfer, use, development, manufacture and marketing of intellectual property. The LES membership includes a wide range of professionals, including business executives, lawyers, licensing consultants, engineers, academicians, scientists and government officials. Many large corporations, professional firms, and universities comprise the Society's membership. Licensing Executives Society (U.S.A. and Canada), Inc. (http://www.usa-canada.les.org/) is a member society of the Licensing Executives Society International, Inc. (LESI), with a worldwide membership of over 12,000 members in 30 national societies, representing over 80 countries.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.